Forest Laboratories
Trial Pipeline
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
NCT02670551
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
NCT01878292
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
NCT01592747
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections
NCT01400867
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
NCT01473394
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
NCT01412060
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
NCT01386112
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
NCT01415531
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
NCT01396447
Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
NCT01298843
Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
NCT01218100
PR-018: An Open-Label, Safety Extension of Study PR-011
NCT01131507
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
NCT01085812
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
NCT01059539
Safety Study of F2695 SR in Major Depressive Disorder
NCT01034267
Open-label Study of Safety and Tolerability of Memantine in Children With Autism
NCT01999894
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT00969709
Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
NCT00765882
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
NCT00694707
Escitalopram in Adult Patients With Major Depressive Disorder
NCT00668525
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
NCT00683592
Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
NCT00633152
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00423657
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
NCT00384436
Acamprosate Initiated During Alcohol Detoxification
NCT00360594
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00314249
Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers
NCT00370110
Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
NCT00111852
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
NCT00035490
Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.
NCT00035464
Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation
NCT00035477
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 17 |
| Phase 4 | 6 |
What the Pipeline for Forest Laboratories Shows
According to the ClinicalTrials.gov registry, Forest Laboratories is linked to 32 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 32 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Forest Laboratories reports 23 late-stage studies (Phase 3 and Phase 4 combined) and 9 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Forest Laboratories is Major Depressive Disorder with 9 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.